News
ABCL
7.55
-0.40%
-0.03
AbCellera: Why I Don't Love This Drug Discoverer's Business Model
Seeking Alpha · 4d ago
AbCellera Biologics: A Post-Covid Future
Seeking Alpha · 5d ago
AbCellera partners with RQ Bio on infectious disease treatments
Seeking Alpha · 6d ago
AbCellera And RQ Bio Partner To Accelerate The Advancement Of New Therapies For Infectious Disease
Benzinga · 6d ago
AbCellera Biologics Forms Partnership With RQ Bio for Infectious Disease Medicines
AbCellera Biologics Forms Partnership With RQ Bio for Infectious Disease Medicines
MT Newswires · 03/22 11:41
BRIEF-Abcellera Biologics Maintains Nominal Amount Of Cash With Silicon Valley Bank To Secure A Corporate Credit Card
Reuters · 03/13 11:53
4 Analysts Have This to Say About AbCellera Biologics
Benzinga · 02/28 16:00
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
Benzinga · 02/28 15:00
AbCellera Biologics (ABCL) Receives a New Rating from Cowen & Co.
TipRanks · 02/28 12:25
Cowen & Co. Initiates Coverage On AbCellera Biologics with Outperform Rating
Benzinga · 02/28 11:22
Cowen Starts AbCellera Biologics at Outperform
Cowen Starts AbCellera Biologics at Outperform
MT Newswires · 02/28 09:03
OmniAb: Legitimate Competition To AbCellera In Antibody Discovery
Seeking Alpha · 02/27 17:16
GDRX, ABCL and BAND are among after hour movers
Seeking Alpha · 02/24 22:22
Oversold Conditions For AbCellera Biologics (ABCL)
NASDAQ · 02/22 16:44
SVB Securities Remains a Buy on AbCellera Biologics (ABCL)
TipRanks · 02/22 16:26
Credit Suisse Sticks to Its Buy Rating for AbCellera Biologics (ABCL)
TipRanks · 02/22 16:26
BMO Capital Maintains Outperform on AbCellera Biologics, Lowers Price Target to $32
Benzinga · 02/22 12:45
Credit Suisse Reiterates Outperform on AbCellera Biologics, Maintains $34 Price Target
Benzinga · 02/22 12:33
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Brookdale Senior Living (BKD), Esperion (ESPR) and AbCellera Biologics (ABCL)
TipRanks · 02/22 12:10
Berenberg Bank Keeps Their Buy Rating on AbCellera Biologics (ABCL)
TipRanks · 02/22 11:45
More
Webull provides a variety of real-time ABCL stock news. You can receive the latest news about Abcellera Biologics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ABCL
AbCellera Biologics Inc. is a technology company that searches, decodes and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. The Company’s full-stack, AI-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. It rebuilds the platform that integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. The Company partners with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.